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Harry C. Dietz
I would like to thank the American Society of Human
Genetics for this great honor. To receive professional rec-
ognition is always gratifying, but to be earmarked for dis-
tinction by a group of people that I so thoroughly admire
and respect is truly extraordinary.
Today, I will talk about my journey with Marfan syn-
drome (MFS). While reflecting about my career during the
preparation for this talk, it was overtly clear to me that I
have simply been blessed, both by my association with
an outstanding institution and, more importantly, with
outstanding people. While training as a pediatric cardi-
ologist, I developed a strong bond with a large population
of individuals with MFS who were followed at Johns Hop-
kins. With conviction that I could best help these people
through research, I approached Victor McKusick, Clair Fan-
comano, and Reed Pyeritz regarding potential laboratory
opportunities. Despite my lack of research experience—I
could guess correctly at the time that A went with T and
G with C about 25% of the time (I won’t dwell on the
fact that this is less success than predicted by chance)—I
was welcomed with open arms. If this remarkable response
set the foundation for my career, the frame was established
by my colleagues at Johns Hopkins, with particular thanks
to Dave Valle and Haig Kazazian for providing guidance
and inspiration. In keeping with the “career as house”
analogy, the incredible young people who have trained in
my lab have been the bricks—I will try to highlight some
of their brilliant contributions throughout this talk—and
the people with MFS and related disorders whom I care
for have been the mortar. I must also recognize the neigh-
bors, my collaborators at other institutions. In particular,
without the keen insight and scientific generosity of Fran-
cesco Ramirez at a vulnerable point in my career, I can
assure you that I would not be here today.
When I arrived to the lab in 1990, it was known that
elastic tissues in MFS show fragmentation and disarray,
with the accumulation of amorphous matrix between fi-
bers. Pioneering work by Lynn Sakai, David Hollister, Reed
Pyeritz, and Peter Byers demonstrated a deficiency of the
connective-tissue protein fibrillin-1 in patient tissues and
abnormalities in fibrillin-1 synthesis, secretion, and/or ma-
trix deposition by cultured cells.1,2 In 1991, a positional-
candidate approach culminated with the knowledge that
mutations in the fibrillin-1 gene (FBN1) on chromosome
15 cause MFS.3–5 Fibrillin-1 monomers aggregate to form
complex extracellular structures called “microfibrils” that
cluster at the margins of maturing elastic fibers during em-
bryogenesis. Early pathogenetic models for MFS focused
on structural weakness of the tissues imposed by micro-
fibrillar deficiency and a postulated consequent failure of
elastogenesis. This boded poorly for the development of
productive treatment strategies. The implication was that
children with MFS are born without sufficient elastic fibers
and therefore have an obligate structural predisposition
for tissue failure later in life. In collaboration with Fran-
cesco Ramirez, our subsequent studies, with use of genet-
ically defined animal models of MFS, demonstrated that
fibrillin-1 is not needed for elastogenesis, as previously
inferred, but, rather, is critical for elastic-fiber mainte-
nance in postnatal life.6,7 Elastic-fiber breakdown corre-
lated both temporally and spatially with a number of pre-
dictable events, including elastic-fiber calcification, local
recruitment of inflammatory cells, and increased expres-
sion of selected matrix-degrading enzymes (specifically,
matrix metalloproteinases [MMPs]2 and9) by resident
vascular smooth-muscle cells.8 Nevertheless, models of
disease pathogenesis continued to singularly invoke an
acquired weakness of the tissues. In retrospect, there are
many manifestations of MFS that are difficult or impos-
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sible to reconcile with such models. For example, why
should weakness of the tissues cause overgrowth of the
bones, myxomatous valve changes, craniofacial dysmor-
phism, low muscle mass, or reduced fat stores? These find-
ings more plausibly relate to abnormalities of cellular per-
formance (proliferation, migration, and/or programmed
death).
A breakthrough in our understanding of the pathogen-
esis of MFS came while studying lung disease in mouse
models. The prior assumption was that air-space widening
simply reflected stress acting on a biomechanically fragile
tissue. The expectation was that the mice would show
normal lungs at birth, with gradual evidence of tissue de-
struction and inflammation, analogous to traditional de-
structive emphysema. Instead, we saw diffuse widening of
the distal air space at birth due to failure of septation of
the prealveolar saccule, with no associated destructive or
inflammatory changes.9 In some manner, a deficiency of
the structural protein fibrillin-1 was impeding the develop-
mental signal for this morphogenetic event. We reasoned
that perhaps this related to altered regulation of and sig-
naling by the TGFb family of cytokines. This hypothesis
was based on the earlier observation that the fibrillins
show significant homology to the latent TGFb-binding
proteins (LTBPs).10–12 It was known that TGFb is secreted
form the cell in the context of a large latent complex (LLC)
composed of the mature cytokine, a dimer of its processed
N-terminal propeptide (latency-associated peptide [LAP]),
and one of three LTBPs. It was also known that the LLC
binds to the matrix, but the binding partner was un-
known, as was the significance of this event. We reasoned
that perhaps microfibrils bind to LTBPs, a hypothesis that
was biochemically validated by Lynn Sakai, Dan Rifkin,
and colleagues,13,14 and that microfibrillar deficiency (as
in MFS) would result in inadequate matrix sequestration,
with consequent promiscuous activation of TGFb. Enid
Neptune and Pam Frischmeyer, in my lab, found increased
free TGFb in the fibrillin-1–deficient lung in association
with reduced LAP (suggesting excessive activation rather
than production of TGFb) and increased activity of a trans-
genic TGFb reporter allele.9 Finally, we showed that sys-
temic administration of TGFb-neutralizing antibody res-
cued lung septation in mouse models of MFS, providing
evidence of a cause-and-effect relationship.9 Our subse-
quent experiments showed that the same process under-
lies other phenotypic manifestations of MFS. Connie Ng
and Dan Judge showed that myxomatous changes of the
mitral valve correlate with increased TGFb signaling, in-
creased output of TGFb-responsive genes (including col-
lagens), excessive cellular proliferation, and reduced ap-
optosis in valve leaflets.15 Once again, TGFb-neutralizing
antibody rescued phenotype.15 Ronni Cohn went on to
show that the low muscle mass and muscle weakness in
MFS reflects failure of muscle regeneration due to TGFb-
induced failure of satellite cells to proliferate and differ-
entiate in response to injury or physiologic signals for
hypertrophy.16 Short-term administration of TGFb-neu-
tralizing antibody restores satellite-cell performance, mus-
cle regeneration, steady-state muscle architecture, and
muscle strength.
The aortic wall in mouse models of MFS shows the pre-
dictable sequence of elastic-fiber fragmentation, aortic-wall
thickening with excess matrix deposition (including col-
lagens, elastin, and proteoglycans), and excessive expres-
sion of MMP-2 and MMP-9. Vacular smooth muscle cells
show nuclear enrichment of phosphorylated Smad2 (p-
Smad2), a direct marker of TGFb signaling, and increased
output of TGFb-responsive gene products, such as con-
nective-tissue growth factor (CTGF).17 In a randomized
and blind trial of TGFb-neutralizing antibody, Jennifer
Habashi and Dan Judge saw a reduced rate of aortic-root
growth and improved aortic-wall architecture—including
improved elastic-fiber maintenance, reduced thickness of
the aortic wall, and decreased collagen deposition—in
mouse models.17
In an attempt to become more clinically relevant, we
asked, “Is there a drug?” and, even better, “Is there an FDA-
approved drug?” that might mimic the effects of TGFb-
neutralizing antibody. Our attention turned to losartan,
an angiotensin II type 1 receptor (AT1) blocker (ARB) that
reduces blood pressure, something that we believe is good
for people with aortic enlargement, and that also had been
shown to reduce fibrosis, at least in part through antag-
onism of TGFb, in animal models of chronic renal dis-
ease.18,19 In a blind and placebo-controlled trial in mice,
Jennifer Habashi and Dan Judge showed that losartan pro-
vided remarkable protection, with normalized aortic-root
growth and aortic dimension and with aortic-wall archi-
tecture that was indistinguishable from that seen in wild-
type mice17 (fig. 1). Evidence suggests that AT1 blockade
reduces expression of TGFb ligands and receptors and also
limits the production of potent activators of TGFb, such
as thrombospondin-1.20–22 Remarkably, losartan also res-
cued other manifestations of MFS in mouse models, in-
cluding pulmonary alveolar septation9 and muscle re-
generation.16 In these tissues, we have observed direct (re-
duced pSmad2) and indirect (reduced collagen and CTGF
expression) evidence of substantial TGFb antagonism in
vivo in response to losartan.
Taken together, these data left us with the firm convic-
tions that (1) most of the multisystem manifestations of
MFS relate to excess TGFb signaling, (2) TGFb antagonism
is a productive treatment strategy for MFS, and (3) Marfan
mouse models could provide a valuable resource for in-
vestigating the roles of TGFb in tissue development and
homeostasis, with relevance to more-common and nonsyn-
dromic presentations of relevant phenotypes, and could
be utilized to assess the therapeutic value of other strat-
egies aimed at TGFb antagonism.
Around this time, Bart Loeys (one of the most excep-
tional physician-scientists that I have encountered) and I
recognized a novel autosomal dominant aortic-aneurysm
syndrome (Loeys-Dietz syndrome [LDS {MIM 609192}])
characterized, in 10 families, by the triad of hypertelorism,
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Figure 1. Representative images of heart and thoracic aorta from
wild-type mice and mice harboring an MFS-associated missense mu-
tation in the Fbn1 gene. Note the dilated ascending aorta (arrow-
heads) in Marfan-affected mice that received either placebo or the
b-adrenergic receptor–blocking agent propranolol (the current stan-
dard of care for people with MFS). In contrast, mutant mice that
received losartan had normal ascending aortic dimensions. This
figure was modified from the work of Habashi et al.17
Figure 2. Features of Loeys-Dietz syndrome. Craniofacial features
include hypertelorism, bifid uvula, and craniosynostosis (arrow).
Cardiovascular features include arterial tortuosity and aneurysms
throughout the arterial tree. This figure was modified from the
works of Loeys et al.23,24
bifid uvula/cleft palate, and arterial tortuosity with ascend-
ing aortic aneurysm and dissection23 (fig. 2). This syn-
drome also presents with multiple other findings, includ-
ing craniosynostosis, Arnold Chiari type I malformation,
pectus deformity, scoliosis, arachnodactyly, club feet, pat-
ent ductus arteriosus, atrial septal defect, bicuspid semi-
lunar valves, and aneurysms/dissections throughout the
arterial tree.23 Evaluation of a larger series of patients con-
firmed that the previously reported triad remains the most
specific finding for this diagnosis.24 This larger study also
confirmed the increased incidence of additional findings,
including developmental delay, hydrocephalus, congeni-
tal hip dislocation, dural ectasia, spondylolisthesis, cer-
vical spine dislocation or instability, submandibular bran-
chial cysts, osteoporosis with multiple fractures at a young
age, and defective tooth enamel. When present, develop-
mental delay did not always associate with either cran-
iosynostosis or hydrocephalus, suggesting that learning
disability is a rare primary manifestation. None of the pa-
tients had ectopia lentis, and dolichostenomelia, a finding
that is typical in MFS, was both rare (18%) and subtle.
On the basis of the central role of TGFb signaling in
cardiovascular, skeletal, and craniofacial development, the
genes encoding the TGFb receptor (TGFBR1 and TGFBR2)
were considered as candidate genes. A prior report had
suggested that heterozygous loss-of-function mutations in
TGFBR2 phenocopy MFS,25 a phenotype with significant
overlap with LDS (aortic-root aneurysm, arachnodactyly,
pectus deformity, dural ectasia, and scoliosis). In our initial
analysis of 10 patients with the classically severe presen-
tation of LDS (including typical craniofacial features [i.e.,
LDS-I]) we found six mutations in TGFBR2 and four in
TGFBR1.23 In a subsequent analysis of 40 patients with
systemic features of both vascular Ehlers-Danlos syndrome
(including joint laxity, easy bruising, dystrophic scars,
translucent skin, organ rupture, and rupture of the gravid
uterus) and LDS (e.g., arterial tortuosity and aneurysms
throughout the arterial tree that tend to tear or rupture
at small dimensions and at a young age) but less severe
or absent craniofacial features (i.e., LDS-II), 12 had mu-
tations in the TGFBR genes.24 To date, we have identified
TGFBR1 or TGFBR2 mutations in 71 probands with either
type of LDS. With rare exceptions, these mutations in-
volve the missense substitution of evolutionarily con-
served residues in the serine-threonine kinase domain of
either TGFb receptor. However, a splice-site mutation in
the extracellular domain and a nonsense mutation in the
penultimate exon, predicted to derive a stable transcript
but a protein product lacking the terminal half of the
kinase domain, led to LDS phenotypes that are indistin-
guishable from those associated with missense mutations.
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There are no differences in phenotype between individ-
uals with mutations in TGFBR1 and TGFBR2 and no ap-
parent phenotype-genotype correlations that explain the
distinction between LDS-I and LDS-II. Furthermore, there
are no apparent differences between the mutations that
we and others have found in patients with LDS versus
those reported as causing typical MFS or familial thoracic
aortic aneurysm and dissection (FTAA).23–31 Indeed, we
have found many of the identical mutations reported as
causing MFS or FTAA in patients with typical LDS-I or LDS-
II.23,24
In the initial description of TGFBR2 mutations causing
MFS, it was observed that expression of mutant receptors
in cells that were naive for TGFb receptors could not sup-
port TGFb signaling.25 Furthermore, there was no apparent
dominant negative interference on the function of coex-
pressed wild-type receptor. These data were interpreted
to infer haploinsufficiency and consequent reduced TGFb
signaling as the relevant pathogenetic mechanisms.25 In
keeping with this hypothesis, one of the original MFS-like
patients was shown to harbor a translocation breakpoint
within the TGFBR2 gene. Complicating this hypothesis,
however, is the observation of a distinct paucity of non-
sense or frameshift mutations in either of the TGFb re-
ceptor genes in patients with LDS or related phenotypes.
Furthermore, the only reported nonsense mutation occurs
at the very distal margin of the penultimate exon.24 As
opposed to more-proximal nonsense mutations, this con-
text is not predicted to induce nonsense-mediated mRNA
decay (NMD) and clearance of the mutant transcripts.32
As a result, most, if not all, mutations in the TGFb receptor
genes associated with vascular phenotypes are predicted
to give rise to a mutant receptor protein that has the ability
to traffic to the cell surface and bind extracellular ligand
but that specifically lack the ability to propagate the intra-
cellular TGFb signal. Furthermore, a model that singularly
invokes decreased TGFb signaling would be difficult to
reconcile with the substantial evidence that many aspects
of MFS, including those that overlap with LDS, are caused
by too much TGFb signaling in animal models and can
be attenuated or prevented by TGFb antagonism in vivo.
We reasoned that perhaps experiments exploring TGFb
signaling in cells that express only mutant receptors were
not informative for the situation in vivo when patients
are heterozygous for these mutations and that perhaps
diminished but not absent function of TGFb receptors in-
itiates chronic and dysregulated compensatory mecha-
nisms that result in too much TGFb signaling.23 Indeed,
the study of fibroblasts derived from heterozygous pa-
tients with LDS failed to reveal any defect in the acute-
phase response to administered ligand and showed an ap-
parent increase in TGFb signaling after 24 hours of ligand
deprivation and a slower decline in the TGFb signal after
restoration of ligand.23 An even more informative result
was the observation of increased nuclear accumulation of
pSmad2 in the aortic wall of patients with either MFS or
LDS and increased expression of TGFb-dependent gene
products such as collagen and CTGF.23 Taken together,
these data demonstrate increased TGFb signaling in the
aortic wall of LDS-affected patients in a context that is
directly relevant to tissue development and homeostasis
in vivo. Whereas the basis for this observation remains
incompletely understood, it seems possible that dysregula-
tion of signaling requires the cell-surface expression of
receptors that can bind TGFb ligands but that can’t prop-
agate signal due to a deficiency in kinase function. In sup-
port of this hypothesis, it was shown that transgenic ex-
pression of a mutant, kinase domain-deleted form of TbRII
leads to increased TGFb signaling, including stimulation
of the intracellular signaling cascade and increased output
of TGFb-responsive genes.33 This is clearly suggestive of a
gain-of-function mechanism for mutant TGFb receptors
in LDS.
In theory, some aspects of the MFS phenotype might
be caused by altered regulation of TGFb signaling, whereas
others might relate to a deficiency of the structural role
of fibrillin-1. A comprehensive consideration of the com-
posite LDS phenotype is very informative in this regard.23,24
The stark observation is that nearly all manifestations of
MFS can be seen in patients with LDS. LDS-affected pa-
tients do not develop lens dislocation and do not tend to
have the same degree of long-bone overgrowth, generally
showing stature that is similar to their unaffected family
members. Under the assumption that all LDS manifesta-
tions reflect altered TGFb signaling, these data suggest that
most manifestations of MFS will be amenable to thera-
peutic strategies aimed at modulating the activity of TGFb.
Preliminary studies performed by Ben Brooke suggest that
losartan can also productively modulate aortic-root growth
in children with severe and rapidly progressive MFS (H.C.D.
and B. Brooke, unpublished data). On the basis of our
studies, the Pediatric Heart Network of the National Heart,
Lung, and Blood Institute has launched a large multicenter
clinical trial of losartan in people with MFS.
The relevance of this work may extend beyond patients
with MFS and related connective-tissue disorders. For ex-
ample, it is interesting to note that the mechanisms of
two aortic aneurysm syndromes (MFS and LDS) converge
on the TGFb-signaling pathway. Recently, in a collabora-
tion led by Paul Coucke and Anne DePaepe, it was dem-
onstrated that loss of function of the facilitative glucose
transporter glut10 causes arterial tortuosity syndrome(ATS),
another systemic vasculopathy.34 On the basis of overlap
with LDS, it was reasoned that perhaps LDS also reflects
too much TGFb activity. We observed increased TGFb sig-
naling in the vessel wall of ATS-affected patients and near-
absent expression of decorin, a negative regulator of TGFb
signaling that shows glucose-dependent expression.34 Mark
Halushka, in the lab, is now investigating whether altered
TGFb signaling underlies other syndromic and nonsyn-
dromic presentations of aortic aneurysm. With similar rea-
soning, Ronni Cohn has now performed studies to show
that excessive TGTb signaling contributes to failed muscle
regeneration and fibrosis in a mouse model of Duchenne
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muscular dystrophy and that losartan can preserve skeletal
muscle architecture and performance in dystrophin-defi-
cient mice.16 Our unpublished data suggest that the failed
ability for muscle regeneration to keep pace with muscle
destruction in selected forms of muscular dystrophy may
also respond to TGFb antagonism with losartan.
The view that the pathogenesis of MFS simply reflects
excessive TGFb activity is undoubtedly an oversimplifica-
tion. It has proven, however, a tractable and productive
reduction of available data. If there are lessons that can
be generalized from our study of MFS, from the perspective
of a clinician who happens to do research to improve the
length and quality of life of patients, they would include
(1) ask clinically relevant questions; (2) keep your eye on
the prize (for MFS, the aorta), but explore the use of other
systems that might provide a more immediate and robust
readout for the elucidation of mechanisms or testing of
therapies (e.g., lung septation); (3) look for net effects,
even if all intermediate steps are not understood; (4) ame-
liorate, if not “cure”; (5) focus on “translatable” strategies;
(6) make aggressive use of animal models; (7) perform
clinical trials, when feasible and appropriate; (8) engage
the participation of individuals from diverse disciplines,
to explore the expanded relevance of new insights; and,
most importantly, (9) recruit and promote trainees who
are much smarter than you are. For those contemplating
combined M.D.-Ph.D. training, I must stress that every
important hypothesis in our work derived directly from a
clinical encounter.
I would like to acknowledge the William S. Smilow Cen-
ter for Marfan Syndrome Research, the National Marfan
Foundation, the National Institutes of Health, and the
Howard Hughes Medical Institute for providing substan-
tial funding, often discretional, which allowed us to ex-
plore all possibilities, not just the derivative “next step.”
I again stress my deep gratitude to my patients, who have
given of themselves, both literally and figuratively, to make
this work possible and who provide enduring inspiration
and motivation. Finally, I thank my wife (and medical
geneticist), Ada Hamosh, and my daughter, Nina Dietz,
for tolerating both my absent minded–professor routine
and the fact that anxiety is my connective tissue. Once
again, I thank you all for this great honor.
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for LDS)
Pediatric Heart Network, http://www.pediatricheartnetwork.org/
marfan.asp
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